Co-Diagnostics has developed a new point-of-care, at-home PCR testing platform to detect Covid-19 and other diseases using CoPrimer technology.
The new diagnostic testing, screening, and surveillance platform is designed to perform the Covid-19 test at businesses, schools, homes, hotels, cruise ships, airports, aeroplanes, and other locations.
Go deeper with GlobalData
It uses the company’s Direct Saliva extraction-free process and Logix Smart test reagents, which are pre-packaged in saliva receptacle tubes.
A person can simply add a swab or saliva sample to the receptacle tube and place the tube inside the small cube-shaped device.
The device can be operated through a smartphone application and delivers rapid PCR Covid-19 results directly to the smartphone.
Co-Diagnostics said that the convenience of displaying the test results on the smartphone enables individuals to quickly know their Covid-19 status and provides a simple way to satisfy the requirements to enter entertainment venues, aeroplane travel, hotel accommodations, work, school, and other applications.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company is planning to revolutionise the PCR test availability as regular Covid-19 testing becomes part of the long-term protocol for many organisations.
Co-Diagnostics CEO Dwight Egan said: “Along with vaccines, social distancing with masks, and high-throughput laboratory testing, we believe that the wide-spread availability of this testing platform will truly give individuals the power to know their Covid-19 status so the world can get back to work, school, travel, and vacations in a Covid-safe environment.”
Additionally, the company expects that the new platform will provide affordable Covid-19 PCR surveillance, screening, and diagnoses to augment tests performed in high-complexity laboratory settings.
Furthermore, the new platform is expected to be available for submission for regulatory approval later this year.
